Effective delivery of hydrophobic drugs to breast and liver cancer cells using a hybrid inorganic nanocarrier: A detailed investigation using cytotoxicity assays, fluorescence imaging and flow cytometry

Manatunga, Danushika C.; Silva, Rohini M. de; Silva, K.M. Nalin de; Malavige, Gathsaurie Neelika; Wijeratne, Dulharie T.; Williams, Gareth R.; Jayasinghe, Chanika D.; Udagama, Preethi

doi:10.1016/j.ejpb.2018.04.001

Cited by 33 publications

(19 citation statements)

References 56 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the work carried out by Manatunga et al, alginate functionalized HAPONH with an iron oxide magnetic core to deliver curcumin and 6‐gingerol targeting breast and liver cancer cells led to sustained release of the drugs at low pH environment (pH 5.3) over 6 to 7 days (Manatunga et al, ). Further the ability of the same HAPONH carrier to act as a dual DDS for curcumin/DOX (Manatunga, de Silva, Nalin de Silva, et al, ) and 6‐gingerol/ DOX (Manatunga, de Silva, de Silva, et al, ) disclose its potential to reduce the MDR and to chemosensitize MCF‐7 and HEpG2 cells (Figure ). Besides, cytocompatibility evaluation on red blood cells, bone marrow and epithelial cells reveal that dual drug‐loaded magnetic HAPONH is devoid of adverse side effects with higher selectivity on cancer cells (Manatunga, de Silva, de Silva, et al, ; Manatunga, de Silva, Nalin de Silva, et al, ).…”

Section: Different Types Of Oinhsmentioning

confidence: 98%

See 1 more Smart Citation

Recent developments in the use of organic–inorganic nanohybrids for drug delivery

Manatunga

Godakanda

Silva

et al. 2019

WIREs Nanomed Nanobiotechnol

Self Cite

View full text Add to dashboard Cite

Organic–inorganic nanohybrid (OINH) structures providing a versatile platform for drug delivery with improved characteristics are an area which has gained recent attention. Much effort has been taken to develop these structures to provide a viable treatment options for much alarming diseases such as cancer, bone destruction, neurological disorders, and so on. This review focuses on current work carried out in producing different types of hybrid drug carriers identifying their properties, fabrication techniques, and areas where they have been applied. A brief introduction on understating the requirement for blending organic–inorganic components into a nanohybrid drug carrier is followed with an elaboration given about the different types of OINHs developed currently highlighting their properties and applications. Then, different fabrication techniques are discussed given attention to surface functionalization, one‐pot synthesis, wrapping, and electrospinning methods. Finally, it is concluded by briefing the challenges that are remaining to be addressed to obtain multipurpose nanohybrid drug carriers with wider applicability. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies

show abstract

Section: Different Types Of Oinhsmentioning

confidence: 98%

“…Codelivery of curcumin and doxorubicin (DOX) via a HAPONH carrier to MCF‐7 and HEpG2 cells, exhibiting a magnetic targeted delivery and pH‐sensitive drug release leading to a higher cell death. (Reprinted with permission from Manatunga, de Silva, Nalin de Silva, et al, (). Copyright 2018 Elsevier Ltd)…”

Section: Different Types Of Oinhsmentioning

confidence: 99%

Recent developments in the use of organic–inorganic nanohybrids for drug delivery

Manatunga

Godakanda

Silva

et al. 2019

WIREs Nanomed Nanobiotechnol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Iron oxide nanoparticles (IONPs) have emerged as theranostic nanoparticles providing a means to address the unmet clinical challenges in the treatment of cancer by imaging drug delivery and tumor response [153–157]. Contemporarily, double receptor targeted iron oxide nanoparticles loaded with paclitaxel drug delivery systems have been developed against prostate cancer [158].…”

Section: Nanomaterials As Drug Delivery Agentsmentioning

confidence: 99%

Current trends and challenges in cancer management and therapy using designer nanomaterials

Navya¹,

et al. 2019

View full text Add to dashboard Cite

Nanotechnology has the potential to circumvent several drawbacks of conventional therapeutic formulations. In fact, significant strides have been made towards the application of engineered nanomaterials for the treatment of cancer with high specificity, sensitivity and efficacy. Tailor-made nanomaterials functionalized with specific ligands can target cancer cells in a predictable manner and deliver encapsulated payloads effectively. Moreover, nanomaterials can also be designed for increased drug loading, improved half-life in the body, controlled release, and selective distribution by modifying their composition, size, morphology, and surface chemistry. To date, polymeric nanomaterials, metallic nanoparticles, carbon-based materials, liposomes, and dendrimers have been developed as smart drug delivery systems for cancer treatment, demonstrating enhanced pharmacokinetic and pharmacodynamic profiles over conventional formulations due to their nanoscale size and unique physicochemical characteristics. The data present in the literature suggest that nanotechnology will provide next-generation platforms for cancer management and anticancer therapy. Therefore, in this critical review, we summarize a range of nanomaterials which are currently being employed for anticancer therapies and discuss the fundamental role of their physicochemical properties in cancer management. We further elaborate on the topical progress made to date toward nanomaterial engineering for cancer therapy, including current strategies for drug targeting and release for efficient cancer administration. We also discuss issues of nanotoxicity, which is an often-neglected feature of nanotechnology. Finally, we attempt to summarize the current challenges in nanotherapeutics and provide an outlook on the future of this important field.

show abstract

“…However, there is a great potential with the limited number of scientists who are actively associated with research in nano-drug carriers, antibacterial agents, and bone prostheses. These include development of bone prostheses (Rajapakse et al, 2016), drug encapsulation, for example, Vitamin C (Samantha Dissanayake et al, 2015), targeted cancer treatment (Katuwavila et al, 2016a;Weerasuriya et al, 2017;Nwokwu et al, 2017;Manatunga et al, 2017;Manatunga et al, 2018a), and developing antimicrobial agents (Peiris et al, 2017;Rathnayake et al, 2018). Rajapakse et al have actively engaged in nano hydroxyapatite-based biomaterials ( Fig.…”

Section: State Of Nanomedicine Research In Sri Lankamentioning

confidence: 99%

“…In addition, in vitro studies on successful biocompatible nanocarriers with magnetic targeting properties ( Fig. 2) have been well explored for many naturally available anticancer agents (Manatunga et al, 2017;Manatunga et al, 2018a) towards breast and liver cancer cells.…”

Section: State Of Nanomedicine Research In Sri Lankamentioning

confidence: 99%

The state of nanomedicine in Sri Lanka: challenges and opportunities

Manatunga

Silva

2018

J of Interdiscip Nanomed

Self Cite

View full text Add to dashboard Cite

Nanomedicine is rapidly expanding in the world due to its potential impact in alleviating various critical problems related to health. In this short review, we highlight the developments in nanomedicine in Sri Lanka through the work carried out by various scientists within the country. Potential challenges in the field and obstacles for conversion to clinical products will also be discussed. Even though there are limited contributions in relation to nano-drug carriers, antibacterial agents, and bone prostheses, the research focused on vaccine development, diagnosis, and imaging tools, and high-throughput screening platforms have not been developed. The main emphasis has been on therapeutic applications and anticancer drug delivery. Many hybrid biocompatible materials have been developed for drug delivery applications; however, work has been limited to in vitro studies due to various reasons. These findings can be extended to in vivo studies by strengthening the collaboration between nanotechnologists and health-related scientists, whose contribution at the clinical stages is paramount. Because of the slow pace of infrastructure development and related policies for clinical trials, many discoveries are terminated at the publication stage. Therefore, product development and commercialization are very challenging in the Sri Lankan context. The attraction of venture capitalists, investors, and government commitment represent current challenges for the product development and implementation of nanomedicine applications within the country.

show abstract

Effective delivery of hydrophobic drugs to breast and liver cancer cells using a hybrid inorganic nanocarrier: A detailed investigation using cytotoxicity assays, fluorescence imaging and flow cytometry

Cited by 33 publications

References 56 publications

Recent developments in the use of organic–inorganic nanohybrids for drug delivery

Recent developments in the use of organic–inorganic nanohybrids for drug delivery

Current trends and challenges in cancer management and therapy using designer nanomaterials

The state of nanomedicine in Sri Lanka: challenges and opportunities

Contact Info

Product

Resources

About